Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
To enable company to be future-ready by tapping potential in CDMO space
Dozee plans to further tap over 2,000 hospitals in more than 100 districts
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
Getinge has a strong market share in India within several product segments
This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
70+ CXOs from leading healthcare institutions across India attended the confluence at Mumbai
Vijaya Hospital, Chennai adopted Dozee’s AI-based contactless continuous remotemonitoring and early warning system to enhance patient safety
Department of Biotechnology is going to play an important part in the integrated holistic healthcare approach against elimination of Tuberculosis
Subscribe To Our Newsletter & Stay Updated
